Trezepatide 30 mg

About Trezepatide

Trezepatide is a linear peptide sequence containing two non-coded aminoisobutyric acid (Aib) residues modified with a C20 fatty diacid moiety. By co-stimulating both GIP and GLP-1 receptors, it demonstrates superior metabolic remodeling and insulin secretion compared to selective single-receptor agonists in preclinical disease models.

Pen technology & delivery format

Trezepatide is supplied in the NADOVA LABS GoQuick pre-filled pen — a graduated, 3 mL dial-calibrated laboratory dispensing system engineered to eliminate reconstitution variability, aerosolization, and volumetric measurement errors in repeat-dose research designs. Each pen is pre-filled with ≥99% HPLC-authenticated research peptide solution, features a tactile dial-a-dose click mechanism, and is preserved under 2–8 °C cold-chain storage with a verifiable batch Certificate of Analysis.

Handling & research compliance

This pre-filled pen is intended strictly for in-vitro and laboratory research use by qualified scientific investigators. It is not an approved medicine, medical device, food, or supplement, and is not for human or veterinary use, ingestion, or injection. Store refrigerated at 2–8 °C, protect from direct light, and follow accepted laboratory safety procedures. Statements have not been evaluated by any regulatory authority (FDA, EMA).